Copiktra (duvelisib) vs Onureg (azacitidine)

Copiktra (duvelisib) is a dual inhibitor of phosphoinositide 3-kinase (PI3K) used primarily for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after at least two prior systemic therapies. Onureg (oral azacitidine) is a hypomethylating agent indicated for the continued treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. When deciding between these medications, it is crucial to consider the specific type of blood cancer being treated, as Copiktra is used for certain types of lymphomas, while Onureg is specifically for maintaining remission in AML, and the decision should be made in consultation with a healthcare provider who can evaluate the individual's medical history and treatment goals.

Difference between Copiktra and Onureg

Metric	Copiktra (duvelisib)	Onureg (azacitidine)
Generic name	Duvelisib	Azacitidine
Indications	Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma	Newly diagnosed acute myeloid leukemia (AML) in patients who are not candidates for intensive induction chemotherapy
Mechanism of action	Phosphoinositide 3-kinase (PI3K) inhibitor	Hypomethylating agent; DNA methyltransferase inhibitor
Brand names	Copiktra	Onureg
Administrative route	Oral	Oral
Side effects	Diarrhea, neutropenia, rash, fatigue, pyrexia, cough, nausea, anemia, upper respiratory infection	Nausea, vomiting, diarrhea, constipation, fatigue, neutropenia, thrombocytopenia, anemia, febrile neutropenia, pneumonia
Contraindications	None known	Advanced malignant hepatic tumors, hypersensitivity to azacitidine or mannitol
Drug class	Antineoplastic agent, PI3K inhibitor	Antineoplastic agent, hypomethylating agent
Manufacturer	Verastem, Inc.	Bristol Myers Squibb

Efficacy

Efficacy of Copiktra (Duvelisib) in Treating Leukemia

Copiktra (duvelisib) is a kinase inhibitor specifically approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) after at least two prior therapies. The efficacy of Copiktra was established in a clinical trial that focused on patients with CLL/SLL. In this study, the overall response rate (ORR) was observed, indicating the percentage of patients who experienced a partial or complete response to the treatment. The ORR for Copiktra in the treatment of CLL/SLL was found to be significant, suggesting that the drug can effectively reduce the disease burden in a substantial number of patients.

Furthermore, Copiktra has also been evaluated for its use in patients with follicular lymphoma (FL) who have received at least two prior systemic therapies. Although FL is a different type of leukemia than CLL/SLL, the efficacy data from the trials provide insight into the drug's activity in a broader leukemia context. Patients with FL showed a meaningful ORR, indicating that Copiktra has potential benefits in various leukemic conditions. However, it is important to note that the safety and efficacy of Copiktra for other types of leukemia beyond CLL/SLL and FL have not been established.

Efficacy of Onureg (Azacitidine) in Treating Leukemia

Onureg (azacitidine) is an oral hypomethylating agent approved for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. The efficacy of Onureg was demonstrated in a pivotal phase 3 study, which showed that maintenance therapy with azacitidine significantly improved overall survival (OS) compared to a placebo. The median OS was notably longer in patients treated with Onureg, highlighting its role in extending the lives of patients with AML in remission.

In addition to improving overall survival, Onureg has shown efficacy in maintaining hematologic remission. This is particularly important for AML patients, as achieving and sustaining remission is a key goal of therapy. The ability of Onureg to prolong the duration of remission after initial therapy can be a critical factor in the management of AML. It is worth mentioning that the use of Onureg for other types of leukemia has not been approved, and its efficacy in these other settings has not been established through clinical trials.

Regulatory Agency Approvals

Copiktra

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Onureg

Food and Drug Administration (FDA), USA

Access Copiktra or Onureg today

If Copiktra or Onureg are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Copiktra

Buy Onureg

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: